Project Grant K24DA061664
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$217K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $208,575 to The McLean Hospital Corporation to expand mentorship of early-career investigators in patient-oriented research on substance use disorders. The award will enable the principal investigator, Dr. R. Kathryn McHugh, to dedicate more time to mentoring current and new mentees, as well as expand her own program of patient-oriented research. Key...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $246,000.00 to The Trustees of Princeton University to investigate the brain mechanisms underlying the therapeutic potential of psilocybin. The research aims to: 1) examine the accelerated acquisition of motivated behavior and task performance after psilocybin administration, and 2) identify the cellular and brain-wide substrates driving...
This Project Grant award of $558,668 from the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs supports research to elucidate the shared and distinct molecular mechanisms underlying the interplay between HIV, substance use disorders (SUD), and neuropsychiatric/neurodegenerative conditions. The award to Massachusetts Institute of Technology (MIT) aims to leverage single-cell transcriptomic, epigenomic, and spatial datasets along with...
This Project Grant award of $2,331,737 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a comprehensive study to investigate the impact of methamphetamine (MA) use on HIV persistence, immune dysfunction, and clinical outcomes among people living with HIV (PWH) on antiretroviral therapy (ART). The study will leverage three unique cohorts to perform the first-in-human investigations directly quantifying MA concentrations in...
This Project Grant award of $616,372 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to identify the role of transposable elements (TEs) in neuroinflammation and transcriptional/epigenetic dysfunction related to HIV-1 infection and cannabinoid use. The research will utilize single-cell/nuclei multiome data from a non-human primate model, post-mortem human brain tissues, and a human brain organoid model adapted...
This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the federal Research and Training in Complementary and Integrative Health program (CFDA 93.213), will fund a feasibility clinical trial to develop and evaluate a Psilocybin-Assisted Cognitive Behavioral Therapy (PA-CBT) protocol for treating major depressive disorder. The $236,250 award, granted on December 17, 2024, supports a 3-year study to refine and optimize the PA-CBT approach, and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This federal Project Grant award, totaling $745,822.00 and provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), supports research to investigate the role of the PERK kinase in HIV-induced neuroinflammation and neurocognitive impairment (NCI) in people with HIV (PWH). The University of Pennsylvania, as the primary grantee, will use biochemical, cellular, and pharmacologic approaches to assess PERK's potential as a predictive...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding research at the University of Oregon to investigate the polypharmacology and psychoplastogenic effects of psychedelic drugs using the C. elegans model organism. The overarching goal is to determine how representative psychedelic compounds, which primarily activate serotonin receptors, influence behavior and neuroplasticity in this invertebrate...
This $194,098 Project Grant award under the National Institute on Drug Abuse's (NIDA) Drug Use and Addiction Research Programs (CFDA 93.279) is designed to provide the principal investigator, Dr. Erath, with mentored training in implementation science to become an independent investigator focused on advancing the implementation of evidence-based treatments for stimulant use disorder and other substance use disorders in harm reduction and community treatment settings. The key objectives of the...